Conditions

Why do some patients respond dramatically to GLP-1 therapies while others see little benefit? This question is becoming more relevant as GLP-1 receptor agonists gain widespread use in diabetes and weight management. Increasingly, clinicians are encountering cases of reduced response to GLP-1 therapies, where expected glycemic or weight outcomes fail …

What happens when a patient does not fit the textbook definition of diabetes care? In real-world practice, uncertainty in diabetes care is more common than many clinicians expect. While guidelines provide a strong foundation, they cannot cover every clinical scenario. As a result, providers often face complex decisions without clear …

The potential link between GLP-1 therapies and gout risk is gaining attention as clinicians look beyond glucose control to broader metabolic outcomes. Patients with obesity and type 2 diabetes often face a dual burden of hyperuricemia and gout, yet these conditions are not always addressed in treatment plans. Could medications …

As GLP-1 receptor agonists become a cornerstone of diabetes care, clinicians are rethinking how often patients on GLP-1 therapy need follow-up visits. These therapies often deliver improved glycemic control, weight loss, and cardiovascular benefits. However, does this stability mean fewer clinic visits, or does it require closer monitoring in new …

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm? Patients with diabetes already face a higher risk of atrial fibrillation, so understanding how these GLP-1 receptor agonists affect cardiac …

A proper baseline assessment for GLP-1 therapy has become a critical yet sometimes overlooked step in modern diabetes care. In fast-moving clinical environments, especially with the rise of telehealth, providers may feel pressure to initiate GLP-1 therapy quickly. However, skipping essential baseline evaluations can lead to missed risks, poor outcomes, …

What happens when a patient walks into your clinic and their diabetes simply doesn’t fit the usual mold? In many cases, clinicians rely on well-established categories like Type 1 or Type 2 diabetes. However, diagnosing atypical forms of diabetes is becoming increasingly important as more patients present with mixed or …

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …

Disease progression in patients using GLP-1 therapies is becoming a critical topic as these medications continue to reshape diabetes care. While GLP-1 receptor agonists improve glycemic control and support weight loss, could they also be hiding deeper metabolic decline? Much like a polished surface that conceals underlying cracks, improved lab …

GLP-1 receptor agonists as adjunct therapy in type 1 diabetes are gaining attention as clinicians look for new ways to improve glycemic control. But is this approach a promising tool or a risky shortcut? As emerging evidence builds, providers must balance potential benefits with safety concerns and patient-specific factors. Table …